---
document_datetime: 2026-01-19 10:00:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aprovel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aprovel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9780916
conversion_datetime: 2026-01-20 20:28:31.981618
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aprovel

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 15/01/2026                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000310720                        | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon. - Accepted C.I.z - to update section 5.3 of the SmPC to implement the recommendation of the CHMP further to EMEA/H/C/WS2502 (CoAprovel, Karvezide) and procedure EMA/VR/0000265130 (CoAprovel, Karvezide). In addition, the MAH took the opportunity to update the details of the local representatives for UK-NI (Deletion) and in IS (Name change) in section 6 of the   |            |     |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000300754 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.1 New certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000265131    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority. - Refused   | 06/11/2025   | N/A   |             |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| Variation type IA_IN / EMA/VR/0000242076 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                    | 11/02/2025   |       | SmPC and PL |